Nucala is available in a pre-filled pen¹.
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult, adolescents and children aged 6 years and older. 1
The recommended dose of Nucala is 100mcg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as a lyophilised powder.
The licence dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks regardless of weight, and is available as a lyophilised powder. 1
The pre-filled formulations are not indicated in 6-11 year olds.
Nucala is administered as a single injection, once every 4 weeks. Patients may need to plan for about 13 injections every year. 1
NUCALA is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. 1
ELIGIBILITY CRITERIA AS DEFINED BY THE HSE
Please refer to the HSE's protocol on use of Mepolizumab for the treatment of severe refractory eosinophilic asthma
- Diagnosed with severe refractory eosinophilic asthma by a Specialist Respiratory Physician
- Adherence to Maintenance Therapy confirmed
- Patient’s inhaler technique has been assessed and the patient has been educated on inhaler use.
- Patient’s compliance with prescribed therapy has been assessed at 3 consecutive monthly visits to CNS, has received adherence advice, PEFR diary and reported asthma outcomes have been assessed or ideally using an adherence measuring device over 3 months. 2
OCS; oral corticosteroids
CNS; Clinical Nurse Specialist
PEFR; Peak Expiratory Flow Rate
Nucala Mode of Action
Watch a visual exploration of Nucala (mepolizumab) and its structure-function relationship.
ED, emergency department; OCS, oral corticosteroids
† Standard of care - High dose ICS and additional maintenance treatment(s)
- Nucala summary of Product Characteristics. Available at www.medicines.ie. Last Accessed November 2020.
- HSE's Mepolizumab (Nucala) Protocol for the treatment of severe refractory eosinophilic asthma, available on www.hse.ie, accessed November 2020.
- Garcia G et al. Eur Respir Rev 2013; 22:251-257.
- Ortega HG et al. Eur Respir J 2014; 44:239-241.